6 results about "Increased Coagulation Activity" patented technology

The invention provides a dual-signal peptide, the dual-signal peptide comprises a first signal peptide and a second signal peptide, the first signal peptide comprises an exogenous signal peptide, the second signal peptide comprises an endogenous signal peptide of a blood coagulation factor VIII, and the first signal peptide and the second signal peptide are connected in series. According to the dual-signal peptide, the secretion effect and the blood coagulation activity of the blood coagulation factor VIII are substantially improved, the production of FVIII can be greatly improved, the industrial production efficiency of FVIII is improved, the application of FVIII in hemophilia treatment drugs is further promoted, and the treatment cost is reduced.

Provided is a dual-signal peptide. The dual-signal peptide comprises a first signal peptide and a second signal peptide, wherein the first signal peptide comprises an exogenous signal peptide, the second signal peptide comprises an endogenous signal peptide of blood coagulation factor VIII, and the first signal peptide and the second signal peptide are linked in tandem. The dual-signal peptide of the present invention enables substantial improvements in both the secretion effect and coagulation activity of blood coagulation factor VIII, so that the yield of FVIII is greatly increased, and the industrial production efficiency thereof is improved.

The present invention relates to a novel sequence of a peptide, characterized by gelling depending on the pH conditions. Since the peptide can induce coagulation, a composition comprising the peptide can be used for inducing hemostasis.

To provide an antibody for factor xa inhibitor and method for using the same.SOLUTION: One of the major limitations of anticoagulant therapy is the limitation of the ability to rapidly reverse anticoagulant activity in the case of treatment-related bleeding risk and in cases of overdosage or required emergency surgical intervention. Therefore, a specific effective antidote for all forms of anticoagulant therapy is highly desirable. The present invention relates to an antidote to an anticoagulant that targets factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives described herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.SELECTED DRAWING: None

This application discloses a method and system for monitoring coagulation activity, wherein the method includes: preparing a first mixture comprising a plurality of microparticles, a blood sample, and a matrix within a bioassay kit; preparing a second mixture comprising the first mixture and a reagent within the bioassay kit; and performing at least two optical detections on the second mixture within the bioassay kit, wherein: the first optical detection of the at least two optical detections includes transmitting a first light beam through a first sidewall of the bioassay kit and the second mixture; and the second optical detection of the at least two optical detections includes transmitting a second light beam through a second sidewall of the bioassay kit and the second mixture.

A high-activity blood coagulation factor XI mutant Ala570Thr (A570T), having nucleotide sequences as shown in SEQ ID NOs: 1-4 and an amino acid sequence as shown in SEQ ID NO: 5, is provided. The mutant is resistant to a physiological inhibitor thereof after being activated from a zymogen state to an active enzyme. Therefore, the mutant has a very high blood coagulation activity and a stronger catalytic ability for a non-physiological substrate; and the mutant is applied to the treatment of hemorrhagic diseases, and has good prospects in terms of gene therapy, gene editing and recombinant protein replacement treatments.